JPS6413026A - Antiviral agent - Google Patents

Antiviral agent

Info

Publication number
JPS6413026A
JPS6413026A JP16956387A JP16956387A JPS6413026A JP S6413026 A JPS6413026 A JP S6413026A JP 16956387 A JP16956387 A JP 16956387A JP 16956387 A JP16956387 A JP 16956387A JP S6413026 A JPS6413026 A JP S6413026A
Authority
JP
Japan
Prior art keywords
sulfate
agent
ribofuranan
antiviral agent
xylopyranan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP16956387A
Other languages
Japanese (ja)
Inventor
Naoki Yamamoto
Hideki Nakajima
Toshiyuki Uryu
Takashi Yoshida
Yutaro Kaneko
Toru Mimura
Hiroshi Matsuzaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Fujirebio Inc
Original Assignee
Ajinomoto Co Inc
Fujirebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc, Fujirebio Inc filed Critical Ajinomoto Co Inc
Priority to JP16956387A priority Critical patent/JPS6413026A/en
Priority to DE19883851386 priority patent/DE3851386T2/en
Priority to EP19880306127 priority patent/EP0298706B1/en
Publication of JPS6413026A publication Critical patent/JPS6413026A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE:To obtain an antiviral agent containing at least one kind of xylofuranan sulfate, ribopyranan sulfate, xylopyranan sulfate and ribofuranan sulfate. CONSTITUTION:At least one kind of xylofuranan sulfate, ribofuranan sulfate, xylopyranan sulfate, ribofuranan sulfate, derivative thereof and salt thereof is blended as an active ingredient and formulated according to a conventional method to provide the aimed product. Used amount thereof is 0.01-2000mg, preferably 0.02-500mg. The agent can be prepared to form of tablet, capsule, elixr, microcapsule or suspension agent. The agent is administered in dozes of 0.01-1000mg per patient several times and in total dozes of 0.02-2000mg daily. The antiviral agent is especially effective in AIDS virus and excellent anti-AIDS viral agent.
JP16956387A 1987-07-07 1987-07-07 Antiviral agent Pending JPS6413026A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP16956387A JPS6413026A (en) 1987-07-07 1987-07-07 Antiviral agent
DE19883851386 DE3851386T2 (en) 1987-07-07 1988-07-06 Use of glycans as antiviral compounds.
EP19880306127 EP0298706B1 (en) 1987-07-07 1988-07-06 Use of glycans in the manufacturing of anti-viral medicaments.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16956387A JPS6413026A (en) 1987-07-07 1987-07-07 Antiviral agent

Publications (1)

Publication Number Publication Date
JPS6413026A true JPS6413026A (en) 1989-01-17

Family

ID=15888785

Family Applications (1)

Application Number Title Priority Date Filing Date
JP16956387A Pending JPS6413026A (en) 1987-07-07 1987-07-07 Antiviral agent

Country Status (1)

Country Link
JP (1) JPS6413026A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009181A1 (en) * 1989-02-10 1990-08-23 Taiho Pharmaceutical Co., Ltd. Anti-hiv drug
US8727536B2 (en) 2007-05-09 2014-05-20 Reald Inc. Polarization conversion system and method for projecting polarization encoded imagery

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62215529A (en) * 1986-01-16 1987-09-22 マツクス−プランク−ゲゼルシヤフト・ツア・フエルデルンク・デア・ヴイツセンシヤフテン・エ−・フアウ Medicinal composition containing reverse transcriptase enzyme inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62215529A (en) * 1986-01-16 1987-09-22 マツクス−プランク−ゲゼルシヤフト・ツア・フエルデルンク・デア・ヴイツセンシヤフテン・エ−・フアウ Medicinal composition containing reverse transcriptase enzyme inhibitor

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009181A1 (en) * 1989-02-10 1990-08-23 Taiho Pharmaceutical Co., Ltd. Anti-hiv drug
US8727536B2 (en) 2007-05-09 2014-05-20 Reald Inc. Polarization conversion system and method for projecting polarization encoded imagery
US9740016B2 (en) 2007-05-09 2017-08-22 Reald Inc. Polarization conversion system and method for projecting polarization encoded imagery
US10203511B2 (en) 2007-05-09 2019-02-12 Reald Inc. Polarization conversion system and method for projecting polarization encoded imagery
US10739611B2 (en) 2007-05-09 2020-08-11 Reald Inc. 3D projection system

Similar Documents

Publication Publication Date Title
HUT61031A (en) Process for producing chemically modified, stable haemoglobin substituting for non-immunogehic red blood cell, and pharmaceutical compositions comprising same as active ingredient
JPS55153715A (en) Prolonged granule of theophylline
JPS57212114A (en) Capsule containing allergen activator and preparation therefor
CA2061917A1 (en) Pediatric effervescent dosage form
HUT55220A (en) Process for producing pharmaceutical composition suitable for systemic administration through the skin and comprising deprenyl as active ingredient
HUT44904A (en) Herbicides comprising 3-phenyl-uracyl derivatives as active ingredient and process for producing the active ingredients and intermediaries thereof
HUT50794A (en) Herbicides comprising substituted benztriazole derivatives as active ingredient and process for producing the active ingredients
NZ221805A (en) Oral, solid, controlled release pharmaceutical dosage form; preparatory processes
ZA876731B (en) Therapeutic agents
HUT45850A (en) Insecticides comprising azolinone derivatives as active ingredient and process for producing the active ingredients
PT91852A (en) PROCESS FOR THE PREPARATION OF PRODUCTS CONTAINING PSYLLIUM
DE68926115D1 (en) METHOD FOR TREATING ACNE
BE890808A (en) NOVEL GALENIC FORM OF ADMINISTRATION OF METOCLOPRAMIDE, ITS PREPARATION METHOD AND MEDICINAL PRODUCT COMPRISING THIS NOVEL FORM
CA2023815A1 (en) Riboflavin granules containing no inactive ingredient
HUT46508A (en) Insecticidal compositions comprising 6-member heterocyclic derivatives of n'-substituted-n,n'-diacylhydrazine and process for producing the active ingredients
FR2712809B1 (en) New pharmaceutical composition intended for the preparation of a stable powder containing, as active ingredient, a combination of acetylsalicylic acid and metoclopramide.
JPS6413026A (en) Antiviral agent
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
EP0310126A3 (en) Derivatives of pyrocatechol-carboxylic acid, their preparation and use as active ingredients in medicines
CA2120001A1 (en) Flavopereirine-based pharmaceutical composition and use thereof for treating hiv
EP0209843A3 (en) Benzylpiperazine compound, preparation thereof, pharmaceutical composition, and use
JPS646214A (en) Remedy for ulcerative colonopathy
HUT46881A (en) Herbicides comprising cyclohexane-1,3,5-triones as active ingredient and process for producing the active ingredients
HUT45995A (en) Pesticides comprising acyloxy-thiophene-urea derivatives as active ingredient and process for producing the active ingredients
AU2065488A (en) The preparation of antigens of human immunodeficiency virus type 1, and the use thereof as diagnostic and therapeutic agent